 Positive results achieved in Phase 3 MOMENTUM study using momelotinib monotherapy for the treatment of myelofibrosis patients who are symptomatic and anemic. Momelotinib has a competitive advantage in that its not a myelosuppressive agent, this means it provides superior efficacy and quality of life compared to currently approved therapies. 